Cancer/testis (CT) antigens exhibit highly tissue-restricted expression and are considered promising targets for cancer vaccines. Here we identified a novel CT gene ZNF645 which restrictively expresses in normal human testes and lung cancer patients (68.3%). To investigate the promoter methylation status of ZNF645, we carried out bisulfite genomic sequencing and found that the CpG island in its promoter was heavily methylated in normal lung tissues without the expression of ZNF645, whereas there was high demethylation in normal human testes and lung carcinoma tissues with its expression. Also ZNF645 could be remarkably activated in A549 and HEK293T cells treated by DNA demethylation agent 5'-aza-2'-deoxycytidine. And the dual luciferase assay revealed that the promoter activity of the ZNF645 was inhibited by methylation of the CpG island region. Therefore, we proposed that ZNF645 is a CT gene and activated in human testis and lung cancers by demethylation of its promoter region. [BMB reports 2010; 43(6): 400-406]
INTRODUCTION
Cancer/testis (CT) antigens are a group of tumor antigens with normal expression restricted to adult male germ cells, but aberrantly expressed in about 40% types of human cancer including lung cancer, and are ideal targets for cancer vaccine (1, 2) . Since the first CT antigen MAGE-1 identified in 1991, more than 130 CT antigens which belong to 83 gene families have been identified. Among them 83 genes are located on X chromosome (3) . It is reported that, about 10% of the genes on the X chromosome are CT antigen genes (4) , and these CT-X genes are notably more testis-restrictively than those on other chromosomes (5) . However, CT proteins expression shows heterogeneous in many cancers including lung carcinoma, therefore more CT antigens need to be identified to develop the polyvalent vaccines to avoid immune escape of tumors (1, 6) .
DNA methylation is considered necessary in suppression of gene transcription and the control of tissue-specific gene activation (7, 8) . By changing chromosome structure and interfering transcription-factor binding, methylation of CpG islands (CGI) within gene promoter results in gene silencing (9) . Epigenetic alterations such as histone deacetylation and DNA methylation are known to play an important role in CT gene expression (10) . For examples, MAGE-A1 transcription is correlated with demethylation of CpG sites in its 5' region (11) and the expression of SSX and NY-ESO-1 can be restored in certain cancer cell lines by the DNA hypomethylating agent 5'-Aza-2'-Deoxycytidine (5'-aza-CdR) (12, 13) .
In searching for testis-specific genes, we found that one gene named ZNF645 located at Xp22.11 from NCBI Unigene database (FLJ25735 fis, clone TST05676; Genbank accession No.: AK098601). In this report, we identified that ZNF645 was specifically expressed in normal human testis and some lung cancer tissues. So it may be a new member of CT gene families. Furthermore, we discovered that the expression of the ZNF645 was primarily regulated by methylation of CpG sites in its promoter region.
RESULTS

ZNF645 gene is restrictively present in human testis among normal somatic tissues and frequently present in some lung cancer tissues
One of the criteria for identifying CT antigen genes is their specific expression in tumors, but not in normal tissues except testis. Here the expression of ZNF645 mRNA was first examined by PCR in 16 different normal human tissues including heart, liver, whole brain, spleen, lung, kidney, pancreas, prostate, ovary, small intestine, colon, peripheral blood, placenta, thymus skeletal muscle and testis, and the results showed that ZNF645 mRNA was only found in normal human testis (Fig.  1A) . Meanwhile the RT-PCR analysis of ZNF645 mRNA expression in paired lung cancer and non-cancerous tissues showed that it was also present in some lung cancer tissues (Fig. 1A) . Furthermore the western blot with whole protein ex-http://bmbreports.org BMB reports These results indicated that ZNF645 may be a novel member of the cancer/testis genes.
Methylation of ZNF645 gene promoter is correlated with its expression in cell lines and primary lung tumors
To understand the mechanism governing the specificity of the ZNF645 gene expression, we investigated the methylation situation of its CpG sites. Firstly we analyzed 5' upstream region of ZNF645 gene by using Methyl Primer Express (Applied Biosystems, USA) and found a typical CpG island (CGI) including 13 CpG sites from −300 bp to −50 bp (length＞300 bp, C+Gs/total bases＞50%, CpG observed/CpG expected＞0.6), which could be potential targets for DNA methylation ( Fig. 2A ) (14, 15) . Then we performed bisulfite genomic sequencing to examine the methylation status of selected ZNF645 CGI in genomic DNA extracted from normal human testis and lung cancer tumors respectively. It was found that the 13 CpGs are highly unmethylated in the normal human testis tissue ( Fig.  2B ) and in two lung neoplasms tissues (Fig. 2C ). In contrast, there was strong methylation in the 13 CpGs in two paired non-cancerous tissue samples. Hence, these methylation data revealed that the expression of ZNF645 was mediated by the methylation status of these CpGs in the 5' upstream region. http://bmbreports.org To further confirm that hypermethylation is responsible for the silencing of the ZNF645, a DNA methyl-transferase inhibitor 5'-aza-CdR was used to treat human embryo kidney cell line 293T and lung cancer cell line A549 cells in which ZNF645 expression is negative. We observed that the expression of ZNF645 was restored on mRNA and protein levels in both cell lines after treatment (Fig. 2D, E) . Then bisulfite sequencing was also used to analyze the DNA methylation status in both cell lines with and without 5'-aza-CdR treatment, and the results showed that the above 13 CpGs was demethylated in those treated cells (Fig. 2F) . All of these results indicated that the expression of ZNF645 in the two cell lines was regulated by the methylation of CGI in the 5' upstream region.
The methylation status of 5' upstream CGI region of ZNF645 mediate the expression of reporter gene luciferase
To examine the effect of methylation status in 5' upstream CGI region of ZNF645 gene in the regulation of gene expression in vitro, we cloned several 5' upstream sequences of ZNF645 and subcloned them into the pGL3 basic reporter vector (Fig.   3A) . Then by transiently transfecting these constructs into HepG2 cells, we observed that the largest construct P1 (−1,140/+115) displayed the highest promoter activity, the transcriptional activity of P4 (−164/+115) was significantly decreased, and P5 (−87/+115) even had no transcriptional activity (Fig. 3A) . These results suggested that the basal promoter of ZNF645 gene was located in the region from −314nt to −87nt. It was especially worth noting that the CGI (−290 to −40) of ZNF645 gene was also mainly located in the region of putative basal promoter.
Then we performed in vitro methylation analysis to confirm whether the promoter activities of ZNF645 gene were inhibited by CGI methylation. The HepG2 cells were transiently transfected with the P1 and P3 promoter constructs methylated with SssI (CpG) methylase and the untreated P1 and P3 mock construct vectors, and the following luciferase activities were measured respectively. As shown in Fig. 3B , the luciferase activities of the methylated ZNF645 promoter constructs were about eight-fold lower than that of mock constructs. And the similar results were also found when transfecting A549 cells (data not shown). These results further confirmed the hypoth-http://bmbreports.org BMB reports esis that the promoter activity of ZNF645 could be repressed by DNA methylation and the expression of ZNF645 was mediated by CGI methylation.
DISCUSSION
Characterization of novel CT antigens is considered promising for cancer immunotherapy. In this study, we identified a novel potential human CT gene ZNF645 which is abundantly expressed in most human lung cancers (68.3%). ZNF645 contains a ring finger C3HC4 domain, a C2H2 domain and a praline-rich region, and is a new member of zinc finger protein family. It is known that there are several zinc finger protein members, such as ZNF165, BORIS, SSX, et al. (16) (17) (18) , which play an important role in carcinomagenesis as CT antigen. We will carry out further investigation on the biological function of ZNF645 in tumor and testis. Genome-wide DNA demethylation is often observed in tumor and male germ cells (19) (20) (21) , and known to be an important mechanism involved in human carcinogenesis and germ-cell development (22) (23) (24) . Expression of CT-X genes always related with globe DNA hypomethylation during tumorigenesis (25) . In this study, we examined the correlation between DNA methylation and the expression of ZNF645. It was observed that there existed DNA hypomethylation of the 5' flanking CGI region of ZNF645 in testis and some lung cancer cases whereas heavy DNA methylation was observed in the same region of the corresponding adjacent non-cancer tissue without ZNF645 expression. Growing evidence suggested that many transcription factors including SP1, CRE, and et al have methylation sensitivity (26) . By using TRANSFAC 4.0 program (http://www.gene-regulation.com) we found that there were several potential binding sites for transcription factors such as GATA-1, C/EBP, SP1 and OCT1 in this CGI region of ZNF645 gene (Data no shown). Hence, the hypermethylation of these CGI sequences may interfere with the activity of these proteins binding in this region, leading to the silence of ZNF645 gene expression.
The demethylation agent 5'-aza-CdR could restore the expression of ZNF645 in HEK293T and A549 cells. Similar results were also described in other CT-X antigens such as MAGE-1 and GAGE (25, 27) . One of the possible mechanisms is that 5'-aza-CdR can inhibit the activity of mammalian DNA methyltransferases (DNMT) (28) . Recent studies showed that the inactivation of two DNA methyltransferases, DNMT1 and DNMT3b, could also induce the abundant expression of CT-X antigen genes in human cancer cells (29) . Hence we propose that the reversible DNA methylation status is necessary to regulate the expression of ZNF645 in cancer cells as well as in normal cells.
In summary, present study first demonstrates that ZNF645 is a novel CT gene and its promoter demethylation is correlated with its expression. Further functional study on the gene would provide evidences for its role in carcinogenesis and male gametogenesis, as well as a novel target for immunotherapeutic vaccination and a biomarker for lung cancer.
MATERIALS AND METHODS
Human specimens
Normal human testes were obtained from a body donor who had died in a car accident. Lung cancer and paired adjacent noncancerous tissue specimens were obtained from West China Hospital, Sichuan University, P.R. China. All tumor and paired noncancerous tissue samples were pathologically confirmed, and informed consent was signed by each donor. This study was approved by the Ethics Committee of West China Hospital, Sichuan University.
RNA isolation and reverse transcription PCR
Normal tissue cDNA panels (multiple tissue cDNA panels I and II) composed of human brain, colon, heart, kidney, leukocytes, liver, lung, ovary, pancreas, placenta, prostate, skeletal muscle, small intestine, spleen, thymus, and testis were purchased from Clontech (Palo Alto, USA). Total RNA was isolated from cell lines and tissues using Trizol reagent (Invitrogen, CA) according to the manufacturer's protocols and 2 μg 
Western blot
Total protein extracted from tissues and cells was separated in 12% SDS-polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride (PVDF) membrane. After blocking with phosphate-buffered saline (PBS) solution containing 10% dry milk, the membranes were sequentially incubated with anti-ZNF645 rabbit polyclonal antibody (Aviva systems biology, USA) at a dilution of 1：1,000 overnight, then, incubated with horse radish peroxidase (HRP) conjugated rabbit anti-human IgG for 1 h, and immunoreactive bands were identified in X-ray films (Kodak, Japan) using chemiluminescent HRP substrate kit (Millipore, USA) with the β-actin as an internal reference.
Immunohistochemistry (IHC)
For detection of ZNF645 protein, 5 μm sections from formalin-fixed, paraffin-embedded tissues were used. After deparaffinized, rehydrated and treated in H2O2 to quench the endogenous peroxidase, the sections were placed in 10 mM citrate buffer (pH 6.0) for antigen retrieval by microwave boiling. After 30 min blocking with 10% normal goat serum to prevent nonspecific antibody binding, sections were incubated with anti-ZNF645 rabbit polyclonal antibody at a dilution of 1： 700 overnight at 4 o C. Following further washes in PBS, horseradish peroxidase-conjugated goat anti-rabbit IgG was applied and incubated for 1 h at 37 o C. Sections were incubated with 3, 3'-diaminobenzidine (DAB) substrate for 2 min and counterstained with hematoxylin solution. Negative control sections were prepared by replacing the primary antibody with non-immune serum from goat.
5'-aza-2'-deoxycytidine (5'-aza-CdR) treatment
To determine the effect of demethylation on the expression of ZNF645 gene, HEK293T and A549 cells were treated with 5'-aza-CdR as previously described (30) . Cells were seeded at low density in six-well plates and treated with 10 μM of 5-aza-CdR for 60 h (Sigma, USA). At the end of treatment, DNA, RNA and total protein were harvested and analyzed as described above.
Bisulfite genomic sequencing
Genomic DNA was extracted from the tissues and cell lines by standard phenol-chloroform methods (31) . Bisulfite treatment was carried out by using the DNA Methylation-Gold kit (Zymo Research, USA) according to the manufacturer's instructions. The PCR amplification was carried out with the following modifications: Semi-nested PCR amplified the CpG island region of the ZNF645 gene promoter; the first PCR primer set was NESTF: 5'-TAGGGTTTGTTGGGAATTTATT-3' and NESTR: PCR products were separated on a 1.5% agarose gel, excised, and gel-purified. TA cloning was used to insert the PCR products into pCRII Vector (Invitrogen, US). The insert was confirmed by restriction digestion and sequenced with the T7/ M13 universal primer. About five subclones were picked for each DNA sample.
Plasmid construction of ZNF645 gene promoters
A pair of primers corresponding to the 5' upstream region of ZNF645 gene was used to amplify the putative promoter regions from the genomic DNA. The forward primers are listed as follows: P1(−1,140/+115), 5'-GGGGTACCATGTGAGGA AATGTGGGCTAA-3'; P2(−572/+115), 5'-GGGGTACCACAT GCACACACACAGACAT-3'; P3(−314/+115), 5'-GGGGTACC GGACAGGGTAGGTGAGGAG-3'; P4(−164/+115), 5'-TCCCC CGGGTCCCTTGTGAGCCGAAAC-3'; P5(−87/+115), 5'-TCCC CCGGGTGGCCTTCACGTTAGCAG-3'. All forward primers carry KpnI restriction sites. And the reverse primer is 5'-CCGCTCGA GCCCAACGGTAACCAGGAAT-3', carrying a restriction site of XhoI. Five fragments were amplified and cut by double enzymes and inserted into pGL3-Basic vectors (Promega, USA) respectively. All above constructs were sequenced.
In vitro methylation
The ZNF645 gene promoter constructs P1 (−1,140/+115) and P3 (−314/+115) were incubated overnight with three units of CpG methyltransferase (M.SssI, New England Biolabs, UK) in presence (methylated) or absence (mock-methylated) of 1mM S-adenosylmethionine, according to the manufacturer's recommendation. After the DNA isolation, 2 μg of the methylated or the mock-methylated reporter constructs were transiently transfected into HepG2 cells and the luciferase activities were measured by the dual-luciferase reporter assay system (Promega, USA).
Transfection and luciferase assay
HepG2 cells were seeded in 24-well plates, cultured in Dulbecco modified Eagle medium (DMEM) overnight and cotransfected with plasmid constructs and pRL-CMV Vector (Pro-http://bmbreports.org BMB reports mega, USA) for 6 hr with Lipofectamine 2000 (Invitrogen, US). Cells were harvested at 48 h after transfection for luciferase activity assay according to the protocol for the dual-luciferase reporter assay system (Promega, USA). The luciferase activity was normalized according to the Renilla luciferase activity.
